“Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT”, J of Skin, vol. 4, no. 6, p. s85, Oct. 2020, doi: 10.25251/skin.4.supp.85.